Eli Lilly pulls Cymbalta journal ads following FDA letter

Share this article:
The FDA has called on Eli Lilly to stop running journal ads for Cymbalta as a treatment for nerve pain caused by diabetes because the ads fail to reveal risks of the drug's use.
In a letter posted on the FDA's Web site last week, the agency said that ads are considered Cymbalta promotion even though their main panels don't mention the drug. Cymbalta, also used as an antidepressant, has risks including dementia if used with older antidepressants known as monoamine oxidase inhibitors.
It can also spur allergic reactions, the FDA said. A Lilly spokesperson told the Bloomberg news agency that the ads appeared in the fourth quarter of 2004 and first quarter of 2005 but won't appear again.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...